Researchers have discovered a new experimental antibody that targets the SFRP2 protein and represents a promising treatment for triple-negative breast cancer (TNBC), one of the most aggressive forms of the disease[2]. This antibody disrupts a key protein that allows cancer cells to survive and escape the immune system[2]. Research has shown that the treatment revived T-lymphocytes, which are often depleted in TNBC, making them more active and effective in fighting the tumor[2]. The SFRP2 protein stands at the intersection of tumor growth, immune suppression, and treatment resistance, making it a suitable target for precision therapy[2]. The new therapy could work alone or in combination with existing immunotherapies and could be effective even in cases where standard treatments fail[2]. This discovery laid the groundwork for a new type of treatment for triple-negative breast cancer that could improve outcomes for patients with this aggressive form of the disease[2].